metadata toggle
Clinical particulars
Target species
Horses and other equines.
Indications for use
A broad spectrum anthelmintic for the treatment and control of adult and immature roundworms of the gastro-intestinal tract in horses and other equines. Panacur also has an ovicidal effect on nematode eggs.
Panacur effectively treats and controls the following roundworm infections:
Large strongyles (adults and migrating larval stages of S.vulgaris; adults and tissue larval stages of S.edentatus).
Benzimidazole susceptible adult and immature small strongyles (Cyathostomes), including encysted mucosal 3rd and 4th stage larvae; it is also effective against encysted inhibited 3rd stage larvae in the mucosa.
Adult and immature Oxyuris spp., Strongyloides spp. and Parascaris equorum.
Contraindications
None.
Special warnings for each target species
Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:
Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
Under dosing, which may be due to underestimation of body weight, misadministration of the product, or lack of calibration of the dosing device (if any).
Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.
Resistance to fenbendazole has been reported in cyathostomes in horses. Therefore the use of this product should be based on local (regional, farm) epidemiological information about susceptibility of nematodes and recommendations on how to limit further selection for resistance to anthelmintics.
Special precautions for use
Assess bodyweight as accurately as possible before calculating the dosage.
Operator warnings
Direct contact with the skin should be kept to a minimum. Wear impermeable rubber gloves while administering the product. Wash hands after use.
Adverse reactions
None known.
Use during pregnancy or lactation
Pregnant mares and foals may be safely treated with fenbendazole at therapeutic dosage levels.
Interactions
None known.
Amounts to be administered and administration route
Routine treatment: Administer orally, 1 Syringe per 600 kg bodyweight
(= 7.5 mg fenbendazole/kg bodyweight)
Practical dosage recommendations:
Weight
Type
Routine treatment
Up to 100 kg
Miniature ponies
Syringe mark 100 kg
101-300 kg
Donkey, Shetland and other small ponies, foals
Syringe mark 300 kg (½ syringe)
301-400 kg
Dartmoor, New Forest, Welsh, etc.
Syringe mark 400 kg
401-500 kg
Light hunter, Arabs, etc.
Syringe mark 500 kg
501-600 kg
Thoroughbreds
Syringe mark 600 kg (1 syringe)
601 kg and over
Heavy hunters, draught horses
1 syringe +additional 100 kg syringe marks for each extra 100 kg bodyweight
Increased dosing for specific infections:
Five day course:
For the treatment and control of migrating and tissue larval stages of large strongyles, encysted mucosal 3rd and 4th stage small strongyle larvae and encysted inhibited 3rd stage small strongyle larvae in the mucosa, administer 1 syringe per 600 kg bodyweight daily for 5 days.
(= 7.5 mg fenbendazole/kg bodyweight daily for 5 days)
Single dose treatments:
For the treatment and control of encysted mucosal stages of small strongyles administer 1 syringe per 150 kg bodyweight.
(= 30 mg fenbendazole/kg bodyweight)
For the treatment and control of migrating stages of large strongyles administer 1 syringe per 75 kg bodyweight.
(= 60 mg fenbendazole/kg bodyweight)
For the treatment and control of Strongyloides westeri in sucking foals administer 1 syringe per 90 kg bodyweight.
(= 50 mg fenbendazole/kg bodyweight)
Panacur Equine Paste should be administered orally by squeezing the paste from the syringe onto the back of the tongue. No dietary control is required before or after treatment.
To ensure administration of a correct dose, body weight should be determined as accurately as possible; accuracy of the dosing device should be checked.
Recommended dosing programme
All horses should be routinely wormed with the single dose of Panacur Equine Paste every 6-8 weeks.
Treatment of encysted inhibited and encysted mucosal dwelling larvae should be performed in the autumn (ideally late October/November) and again in the spring (ideally in February). However, for horses who fail to maintain condition or bought-in horses with unknown worming history, the treatment can be given at any time of the year.
Overdose
Benzimidazoles have a high margin of safety.
Withdrawal periods
Not to be used in horses intended for human consumption.
Treated horses may never be slaughtered for human consumption.
The horse must have been declared as not intended for human consumption under national horse passport legislation.